Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Interest & Investment Income: 2010-2025

Historic Interest & Investment Income for Madrigal Pharmaceuticals (MDGL) over the last 11 years, with Sep 2025 value amounting to $10.3 million.

  • Madrigal Pharmaceuticals' Interest & Investment Income fell 20.82% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year decrease of 12.45%. This contributed to the annual value of $46.7 million for FY2024, which is 138.30% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Interest & Investment Income stood at $10.3 million for Q3 2025, which was up 25.29% from $8.2 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Interest & Investment Income high stood at $14.2 million for Q2 2024, and its period low was $52,000 during Q4 2021.
  • For the 3-year period, Madrigal Pharmaceuticals' Interest & Investment Income averaged around $8.6 million, with its median value being $9.0 million (2023).
  • In the last 5 years, Madrigal Pharmaceuticals' Interest & Investment Income crashed by 95.13% in 2021 and then surged by 5,372.46% in 2023.
  • Madrigal Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $52,000 in 2021, then surged by 1,969.23% to $1.1 million in 2022, then soared by 732.06% to $9.0 million in 2023, then grew by 23.75% to $11.1 million in 2024, then fell by 20.82% to $10.3 million in 2025.
  • Its Interest & Investment Income was $10.3 million in Q3 2025, compared to $8.2 million in Q2 2025 and $9.4 million in Q1 2025.